Prolonged coenzyme Q10 treatment in Down syndrome patients, effect on DNA oxidation

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 626.e1-626.e8

  Tiano, Luca ^a   Padella, Lucia ^a   Santoro, Lucia ^a   Carnevali, Paola ^a   Principi, Federica ^a   Brugè, Francesca ^a   Gabrielli, Orazio ^a   Littarru, Gian Paolo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Comet assay; Down syndrome; Oxidative DNA damage

Indexed keywords

ALLANTOIN; DNA; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; ENDONUCLEASE III; MITOQUINONE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UBIDECARENONE; UNCLASSIFIED DRUG; URIC ACID; DRUG DERIVATIVE; MULTIENZYME COMPLEX; UBIQUINONE; VITAMIN;

ADOLESCENT; AGE DISTRIBUTION; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CELL COUNT; CHILD; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DNA REPAIR; DOWN SYNDROME; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LEUKOCYTE; MALE; METHODOLOGY; OXIDATIVE STRESS; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; AGING; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LYMPHOCYTE; METABOLISM; THROMBOCYTE; TIME; TREATMENT OUTCOME;

ADOLESCENT; AGING; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DNA DAMAGE; DOWN SYNDROME; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HUMANS; LYMPHOCYTES; OXIDATIVE STRESS; TIME FACTORS; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 80054874295     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.03.025     Document Type: Article

References (29)

1. Borrás C., Gambini J., Gómez-Cabrera M.C., Sastre J., Pallardó F.V., Mann G.E., Viña J. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFkappaB cascade. Aging Cell 2005, 4:113-118.
2. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
3. Capone G.T. Down syndrome: advances in molecular biology and the neurosciences. J. Dev. Behav. Pediatr 2001, 22:40-59.
4. Contestabile A., Benfenati F., Gasparini L. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol 2010, 91:1-22.
5. Conti A., Fabbrini F., D'Agostino P., Negri R., Greco D., Genesio R., D'Armiento M., Olla C., Paladini D., Zannini M., Nitsch L. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 2007, 8:268.
6. Estornell E., Fato R., Castelluccio C., Cavazzoni M., Parenti Castelli G., Lenaz G. Saturation kinetics of coenzyme Q in NADH and succinate oxidation in beef heart mitochondria. FEBS Lett 1992, 311:107-109.
7. Gillespie K.M., Chae J.M., Ainsworth E.A. Rapid measurement of total antioxidant capacity in plants. Nat. Protoc 2007, 2:867-870.
8. Groneberg D.A., Kindermann B., Althammer M., Klapper M., Vormann J., Littarru G.P., Döring F. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int. J. Biochem. Cell Biol. 2005, 37:1208-1218.
9. Iannello R.C., Crack P.J., de Haan J.B., Kola I. Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. Suppl 1999, 57:257-267.
10. Jovanovic S.V., Clements D., MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med 1998, 25:1044-1048.
11. Lim P., Wuenschell G.E., Holland V., Lee D.H., Pfeifer G.P., Rodriguez H., Termini J. Peroxyl radical mediated oxidative DNA base damage: implications for lipid peroxidation induced mutagenesis. Biochemistry 2004, 43:15339-15348.
12. Littarru G.P., Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition 2010, 26:250-254.
13. Loft S., Høgh Danielsen P., Mikkelsen L., Risom L., Forchhammer L., Møller P. Biomarkers of oxidative damage to DNA and repair. Biochem. Soc. Trans 2008, 36:1071-1076.
14. Maluf S.W., Erdtmann B. Genomic instability in Down syndrome and Fanconi anemia assessed by micronucleus analysis and single-cell gel electrophoresis. Cancer Genet. Cytogenet 2001, 124:71-75.
15. Miles M.V., Patterson B.J., Chalfonte-Evans M.L., Horn P.S., Hickey F.J., Schapiro M.B., Steele P.E., Tang P.H., Hotze S.L. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy. Pediatr. Neurol 2007, 21:398-403. 37.
16. Morawiec Z., Janik K., Kowalski M., Stetkiewicz T., Szaflik J., Morawiec-Bajda A., Sobczuk A., Blasiak J. DNA damage and repair in children with Down's syndrome. Mutat. Res 2008, 637:118-123.
17. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol 2001, 60:759-767.
18. Pallardó F.V., Degan P., d'Ischia M., Kelly F.J., Zatterale A., Calzone R., Castello G., Fernandez-Delgado R., Dunster C., Lloret A., Manini P., Pisanti M.A., Vuttariello E., Pagano G. Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology 2006, 7:211-220.
19. Pincheira J., Navarrete M.H., de la Torre C., Tapia G., Santos M.J. Effect of vitamin E on chromosomal aberrations in lymphocytes from patients with Down's syndrome. Clin. Genet 1999, 55:192-197.
20. Raji N.S., Rao K.S. Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech. Ageing Dev 1998, 100:85-101.
21. Schmelzer C., Lindner I., Vock C., Fujii K., Döring F. Functional connections and pathways of coenzyme Q10-inducible genes: an in-silico study. IUBMB Life 2007, 59:628-633.
22. Seidl R., Greber S., Schuller E., Bernert G., Cairns N., Lubec G. Evidence against increased oxidative DNA-damage in Down syndrome. Neurosci. Lett 1997, 17:137-140.
23. Sekine K., Ota N., Nishii M., Uetake T., Shimadzu M. Estimation of plasma and saliva levels of coenzyme Q10 and influence of oral supplementation. Biofactors 2005, 25:205-211.
24. Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease. Nat. Clin. Pract. Neurol 2007, 3:162-172.
25. Tarnopolsky M.A. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv. Drug Deliv. Rev 2008, 60:1561-1567.
26. Tiano L., Carnevali P., Padella L., Santoro L., Principi F., Brugè F., Carle F., Gesuita R., Gabrielli O., Littarru G.P. Effect of Coenzyme Q(10) in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial. Neurobiol. Aging 2009, 10.1016/j.neurobiolaging.2009.11.016.
27. Tomasetti M., Alleva R., Borghi B., Collins A.R. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J 2001, 15:1425-1427.
28. Zana M., Janka Z., Kálmán J. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 2007, 28:648-676.
29. Zana M., Szécsényi A., Czibula A., Bjelik A., Juhász A., Rimanóczy A., Szabó K., Vetró A., Szucs P., Várkonyi A., Pákáski M., Boda K., Raskó I., Janka Z., Kálmán J. Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem. Biophys. Res. Commun 2006, 345:726-733.